Close

ORALAIR® IMPORTANT SAFETY INFORMATION

Initiate treatment with ORALAIR 4 months before the expected onset of each grass pollen season and maintain it throughout the grass pollen season.1

IMPORTANT SAFETY INFORMATION

WARNING: SEVERE ALLERGIC REACTIONS

  • ORALAIR can cause life-threatening allergic reactions such as anaphylaxis and severe laryngopharyngeal edema.
  • Do not administer ORALAIR to patients with severe, unstable or uncontrolled asthma.
  • Observe patients in the office for at least 30 minutes following the initial dose.
  • Prescribe auto-injectable epinephrine, instruct and train patients on its appropriate use, and instruct patients to seek immediate medical care upon its use.
  • ORALAIR may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious allergic reaction.
  • ORALAIR may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers.

ORALAIR is contraindicated in patients with severe, unstable or uncontrolled asthma, patients with a history of any severe systemic allergic reaction or severe local reaction to sublingual allergen immunotherapy, or patients who are hypersensitive to any of the inactive ingredients.

ORALAIR can cause systemic allergic reactions, including anaphylaxis, and severe local reactions, including laryngopharyngeal swelling, which may be life-threatening. Severe and serious allergic reactions may require treatment with epinephrine. Patients who have a systemic allergic reaction to ORALAIR should stop taking the product. ORALAIR treatment should be withheld if the patient is experiencing an acute asthma exacerbation. Re-evaluate patients who have recurrent asthma exacerbations and consider discontinuation of ORALAIR. Concomitant dosing with other allergen immunotherapy may increase the likelihood of local or systemic adverse reactions to either subcutaneous or sublingual allergen immunotherapy.

In case of oral inflammation or wounds, such as following oral surgery or dental extraction, ORALAIR treatment should be discontinued to allow complete healing of the oral cavity.

The most common adverse events reported in ≥5% of patients were oral pruritus, throat irritation, ear pruritus, mouth edema, tongue pruritus, cough, and oropharyngeal pain. Patients who have escalating or persistent local reactions to ORALAIR should be reevaluated and considered for discontinuation of ORALAIR.

ORALAIR should be used during pregnancy or breastfeeding only if clearly needed.

Please see full Prescribing Information, including Boxed Warning and Medication Guide, by clicking this link.

References:

  1. ORALAIR (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract) full prescribing information. Stallergenes S.A. 2014.

GREER® EXTRACTS IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION:

WARNING: ANAPHYLAXIS

  • Do not inject intravenously.
  • Allergenic extracts may cause severe life-threatening systemic reactions, including the rare occurrence of anaphylaxis or death. Systemic reactions include: generalized skin erythema, urticaria, pruritus, angioedema, rhinitis, wheezing, laryngeal edema and hypotension. Other adverse reactions include: nausea, emesis, abdominal cramps, and diarrhea.
  • Intended for use only by physicians who are experienced in the administration of allergenic extracts. Initial dose must be based on skin test.
  • Observe patients in the office for at least 30 minutes following treatment. Emergency measures and personnel trained in their use must be available immediately in the event of a life threatening reaction. Immunotherapy may not be suitable for patients with medical conditions that reduce their ability to survive a systemic reaction.

Please see Package Inserts for full prescribing information including Boxed Warning by clicking this link.

Comprehensive Allergy Immunotherapy Solutions from GREER®

Get in touch with your GREER® Allergy Sales Consultant, Customer Care Specialist, or Medical & Scientific Affairs team for answers to your allergy immunotherapy questions.

GREER offers a broad selection of high-quality extracts for testing and treatment, sterile diluents, sterile empty vials, and single- and multiple-site skin testing devices.

The GREER allergy immunotherapy treatment options include GREER® Extracts™ and ORALAIR® (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract) tablet for sublingual use.

Oralair

ORALAIR is an allergen extract indicated as immunotherapy for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for any of the 5 grass species contained in this product.

ORALAIR is approved for use in persons 10 through 65 years of age.

ORALAIR is not indicated for the immediate relief of allergy symptoms.

Initiate treatment with ORALAIR 4 months before the expected onset of each grass pollen season and maintain it throughout the grass pollen season.1

CLICK HERE to visit ORALAIR.com to learn more about the first and only sublingual grass allergy immunotherapy tablet with a mixed pollens allergen extract from 5 grasses.

Please see Important Safety Information, including Boxed Warning, below and click here for full Prescribing Information and Medication Guide.

 

Allergenic extracts are indicated for skin test diagnosis and treatment (immunotherapy) of patients with seasonal and perennial allergies.

Please see Important Safety Information, including Boxed Warning, below and click here for Package Inserts.

 

References:

  1. ORALAIR (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract) full prescribing information. Stallergenes S.A. 2014.

GREER® Skin Testing
Proficiency Program®

GREER Skin Testing Proficiency Program

The GREER Skin Testing Proficiency program was created in response to the growing trend toward standardization in allergy immunotherapy practices. This proprietary program is designed to optimize the accuracy, precision, and safety of skin testing.

Click here to learn more about the GREER Skin Testing Proficiency Program

 

GREER Service Team

With your GREER® Service Team, you have GREER professionals ready to help you and your practice.

Do you have a challenge or question you
need help with right away?
Get in touch with GREER®

Toll Free: 800.378.3906
Fax: 800.419.7302
Email: .(JavaScript must be enabled to view this email address)


 

Privacy Policy | Terms & Conditions | Site Map

All material and content herein Copyright © 2014 GREER. No material from this website may be used, reproduced or copied in whole or in part without prior written permission from GREER.
All Rights Reserved Worldwide.

ORALAIR® IMPORTANT SAFETY INFORMATION
Expand

Initiate treatment with ORALAIR 4 months before the expected onset of each grass pollen season and maintain it throughout the grass pollen season.1

IMPORTANT SAFETY INFORMATION

WARNING: SEVERE ALLERGIC REACTIONS

GREER® EXTRACTS IMPORTANT SAFETY INFORMATION
Expand

IMPORTANT SAFETY INFORMATION:

WARNING: ANAPHYLAXIS

  • Do not inject intravenously.
  • Allergenic extracts may cause severe life-threatening systemic reactions, including the rare occurrence of anaphylaxis or death. Systemic reactions include: generalized skin erythema, urticaria, pruritus, angioedema, rhinitis, wheezing, laryngeal edema and hypotension. Other adverse reactions include: nausea, emesis, abdominal cramps, and diarrhea.